3 Custom API Manufacturing, Specialty Formulations and Acute Therapy Brands Stocks With a Strong Future Roadmap: Neuland Laboratories, Rubicon Research and Alkem Laboratories

API and formulation growth stocks let investors follow companies that make the ingredients and the finished medicines behind modern treatment. Neuland Laboratories, Rubicon Research and Alkem Laboratories cover custom API manufacturing, specialty formulations and a leading acute therapy franchise.

This list covers three API and formulation growth stocks with complete current figures: Neuland Laboratories, Rubicon Research and Alkem Laboratories. Every figure comes from the latest reported financials and the 21 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are API and Formulation Growth Stocks?

API and formulation growth stocks are listed pharmaceutical companies that make active ingredients, specialty formulations or branded medicines for patients and drug marketers. Their earnings depend on customer programmes, approvals and prescription trends.

API and Formulation Growth Stocks at a Glance

On valuation, Alkem Laboratories trades at a P/E below the industry P/E, while Neuland Laboratories and Rubicon Research trade above it, which reflects the growth the market already expects. Readers comparing API and formulation growth stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do API and Formulation Growth Stocks Have a Strong Roadmap in India?

API and formulation growth stocks have a strong roadmap in India because drug developers are outsourcing complex manufacturing and domestic demand for acute and chronic therapies keeps rising.

• Custom manufacturing. Innovator companies share production of complex molecules with Indian partners.
• Specialty products. Differentiated formulations earn better pricing than basic generics.
• Domestic brands. Strong acute care brands build steady prescription demand.

Why Neuland Laboratories Features Among These API and Formulation Growth Stocks

Among the API and formulation growth stocks on this list, Neuland Laboratories, based in Hyderabad, makes active pharmaceutical ingredients for generic drugs and runs a custom manufacturing business that supplies innovator companies.

The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P/E of 49.5, above the industry P/E of 36.0.

Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%.

Roadmap: The company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.

What to watch: Custom manufacturing revenue can move between quarters, so review the full-year trend.

Why Rubicon Research Features Among These API and Formulation Growth Stocks

Among the custom manufacturing pharma shares on this list, Rubicon Research is a pharmaceutical formulations company that develops and sells specialty and complex generic products, with the United States as its main market.

Revenue rose from Rs 330 crore in FY22 to Rs 1,762 crore in FY26, a compound annual growth rate of 52.0%. Net profit grew from Rs 91.0 crore in FY24 to Rs 247 crore in FY26, which works out to a compound annual growth rate of 64.7%.

In the June 2026 quarter, revenue grew 52.9% year on year to Rs 540 crore, while net profit rose 95.8% to Rs 84.8 crore. The company has a return on equity of 19.1%, a debt to equity ratio of 0.24 and a market capitalisation of Rs 24,654 crore. The stock trades at a P/E of 85.5, above the industry P/E of 36.0.

Roadmap: The company builds differentiated products that need technical skill and earn better pricing than basic generics. A growing list of approved products and an own-label model give it room to widen its portfolio.

What to watch: Follow new product approvals and launches in the United States.

Why Alkem Laboratories Features Among These API and Formulation Growth Stocks

Among the three companies on this list, Alkem Laboratories is a Mumbai-based pharmaceutical company with a leading domestic franchise in anti-infectives, gastro-intestinal, pain and vitamins, along with exports of generics and a contract manufacturing and active ingredient business.

In the June 2026 quarter, revenue grew 11.0% year on year to Rs 3,893 crore. Revenue rose from Rs 10,797 crore in FY22 to Rs 15,296 crore in FY26, a compound annual growth rate of 9.1%.

Net profit grew from Rs 1,680 crore in FY22 to Rs 2,353 crore in FY26, which works out to a compound annual growth rate of 8.8%. The company has a return on equity of 16.7%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 59,723 crore. The stock trades at a P/E of 27.1, below the industry P/E of 36.0.

Roadmap: Alkem's strong domestic brands and wide medical representative network support steady growth, while its international business adds regulated market exposure. The company is also building its chronic and specialty portfolio and its biosimilars pipeline.

What to watch: Check the growth in chronic therapies in India and the contribution from the international and contract manufacturing businesses.

Neuland Laboratories vs Rubicon Research vs Alkem Laboratories on Key Financials

The table below sets the three API and formulation growth stocks side by side on revenue, profit and margin, using reported figures.

Neuland Laboratories posts the highest return on equity in this group at 19.4%. Alkem Laboratories has the largest FY26 revenue at Rs 15,296 crore, and Rubicon Research shows the fastest revenue growth with a 52.0% compound annual rate. A useful habit with API and formulation growth stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in API and Formulation Growth Stocks

Every theme carries risks that deserve a check before any decision. For these API and formulation growth stocks, the main points are:

• Programme timing. Revenue from custom projects can vary between quarters.
• Approval timelines. Launches depend on regulatory decisions that can shift.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter API and formulation growth stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on API and Formulation Growth Stocks

API and formulation growth stocks reward investors who follow customer programmes, approvals and brand growth together. Neuland Laboratories, Rubicon Research and Alkem Laboratories each address a different link in the chain. Based on the 21 October 2026 close, Neuland Laboratories trades at Rs 18,975, Rubicon Research at Rs 1,448.5 and Alkem Laboratories at Rs 5,015.

Download the Univest iOS App or Univest Android App to track API and formulation growth stocks, set price alerts and get research-backed stock ideas.

What are API and formulation growth stocks?

Ans. API and formulation growth stocks are listed pharmaceutical companies that make active ingredients, specialty formulations or branded medicines for patients and drug marketers. Their earnings depend on customer programmes, approvals and prescription trends. This list looks at three of them, Neuland Laboratories, Rubicon Research and Alkem Laboratories, using reported FY22 to FY26 financials and the 21 October 2026 closing prices.

Which API and formulation growth stocks are covered in this list?

Ans. This list covers Neuland Laboratories, Rubicon Research and Alkem Laboratories. Based on the 21 October 2026 close, Neuland Laboratories traded at Rs 18,975, Rubicon Research at Rs 1,448.5 and Alkem Laboratories at Rs 5,015. Their return on equity ranges from 16.7% to 19.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.1% to 52.0%.

Why do API and formulation growth stocks have a strong future roadmap in India?

Ans. API and formulation growth stocks have a strong roadmap in India because drug developers are outsourcing complex manufacturing and domestic demand for acute and chronic therapies keeps rising. The main drivers are as follows. Custom manufacturing. Innovator companies share production of complex molecules with Indian partners. Specialty products. Differentiated formulations earn better pricing than basic generics. Domestic brands. Strong acute care brands build steady prescription demand. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Neuland Laboratories performed financially?

Ans. Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P/E of 49.5, above the industry P/E of 36.0. Looking ahead, the company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.

How has Rubicon Research performed financially?

Ans. Revenue rose from Rs 330 crore in FY22 to Rs 1,762 crore in FY26, a compound annual growth rate of 52.0%. Net profit grew from Rs 91.0 crore in FY24 to Rs 247 crore in FY26, which works out to a compound annual growth rate of 64.7%. In the June 2026 quarter, revenue grew 52.9% year on year to Rs 540 crore, while net profit rose 95.8% to Rs 84.8 crore. The company has a return on equity of 19.1%, a debt to equity ratio of 0.24 and a market capitalisation of Rs 24,654 crore. The stock trades at a P/E of 85.5, above the industry P/E of 36.0. Looking ahead, the company builds differentiated products that need technical skill and earn better pricing than basic generics. A growing list of approved products and an own-label model give it room to widen its portfolio.

How has Alkem Laboratories performed financially?

Ans. Revenue rose from Rs 10,797 crore in FY22 to Rs 15,296 crore in FY26, a compound annual growth rate of 9.1%. Net profit grew from Rs 1,680 crore in FY22 to Rs 2,353 crore in FY26, which works out to a compound annual growth rate of 8.8%. In the June 2026 quarter, revenue grew 11.0% year on year to Rs 3,893 crore. The company has a return on equity of 16.7%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 59,723 crore. The stock trades at a P/E of 27.1, below the industry P/E of 36.0. Looking ahead, alkem's strong domestic brands and wide medical representative network support steady growth, while its international business adds regulated market exposure. The company is also building its chronic and specialty portfolio and its biosimilars pipeline.

What risks should investors check before buying API and formulation growth stocks?

Ans. Investors should check a few risks before buying API and formulation growth stocks. Programme timing. Revenue from custom projects can vary between quarters. Approval timelines. Launches depend on regulatory decisions that can shift. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of API and formulation growth stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 21 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.